{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:19:38Z","timestamp":1783343978849,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Serum sialic acid binding immunoglobulin-like lectin-1 (sSIGLEC-1) is a type I interferon-associated biomarker previously linked to lupus nephritis (LN) in European ancestry populations, but its utility in non-European cohorts remains poorly defined. This study aimed to validate the association of sSIGLEC-1 with LN in Egyptian SLE patients (non-European ancestry) and to test its correlation with world health organization (WHO) pathological classes, chronic kidney disease (CKD) stages, systemic lupus international collaborating clinics-renal activity score (SLICC-RAS), systemic lupus erythematosus disease activity index (SLEDAI), 24-hour urinary protein and proinflammatory cytokines. This cross-sectional study included 80 SLE patients (47 with LN, 33 without LN) and 20 healthy controls. Renal biopsy was classified according to WHO criteria. Estimated glomerular filtration rate (eGFR) and CKD stages were calculated. Median levels of sSIGLEC-1 were significantly higher in SLE patients than controls (113.5 vs. 11.2 pg\/mL) and in LN patients than non-LN patients (117.7 vs. 110.0 pg\/mL). Multivariable logistic regression confirmed sSIGLEC-1 as an independent predictor of LN (OR\u2009=\u20091.02,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04). sSIGLEC-1 correlated positively with SLEDAI (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.26), SLICC-RAS (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.31), and proinflammatory cytokines (IL-1\u03b2, IL-6, TNF-\u03b1), but did not correlate with 24-hour urinary protein (\n                    <jats:italic>r<\/jats:italic>\n                    = \u2212\u20090.175). However, no significant differences in sSIGLEC-1 were observed across WHO pathological classes or CKD stages. ROC analysis showed poor discriminative ability for LN (AUC\u2009=\u20090.6928, sensitivity 93.6%, specificity 39.4%). In Egyptian SLE patients, sSIGLEC-1 is elevated in LN and correlates with disease activity but does not reflect histological severity or chronic kidney damage. Its low specificity limits diagnostic utility; however, high sensitivity suggests potential as a rule-out screening test for LN in non-European populations.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-60610-x","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:27:48Z","timestamp":1783340868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum sialic acid binding immunoglobulin-like lectin-1 (sSIGLEC-1) in Egyptian patients with lupus nephritis: correlation with renal activity in non-European ancestry"],"prefix":"10.1038","volume":"16","author":[{"given":"Samar","family":"Magdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Wadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyaa","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-2479","authenticated-orcid":false,"given":"Mohamed","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"60610_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.cyto.2012.07.004","volume":"60","author":"KF Koenig","year":"2012","unstructured":"Koenig, K. F. et al. Serum cytokine profile in patients with active lupus nephritis. Cytokine 60, 410\u2013416 (2012).","journal-title":"Cytokine"},{"key":"60610_CR2","doi-asserted-by":"publisher","first-page":"365083","DOI":"10.1155\/2010\/365083","volume":"2010","author":"DY Yap","year":"2010","unstructured":"Yap, D. Y. & Lai, K. N. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: From basics to recent advances. J. Biomed. Biotechnol. 2010, 365083 (2010).","journal-title":"J. Biomed. Biotechnol."},{"key":"60610_CR3","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.2337\/dc08-0168","volume":"31","author":"K Hamano","year":"2008","unstructured":"Hamano, K., Nitta, A., Ohtake, T. & Kobayashi, S. Associations of renal vascular resistance with albuminuria and other microangiopathy in type 2 diabetic patients. Diabetes Care. 31, 1853\u20131857 (2008).","journal-title":"Diabetes Care"},{"key":"60610_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan, S. & Paulson, J. C. Siglecs as immune cell checkpoints in disease. Annu. Rev. Immunol. 38, 365\u2013395 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"60610_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cbpa.2021.01.001","volume":"62","author":"G Murugesan","year":"2021","unstructured":"Murugesan, G., Weigle, B. & Crocker, P. R. Siglec and anti-Siglec therapies. Curr. Opin. Chem. Biol. 62, 34\u201342 (2021).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"60610_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","volume":"77","author":"H L\u00e4ubli","year":"2020","unstructured":"L\u00e4ubli, H. & Varki, A. Sialic acid\u2013binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses. Cell. Mol. Life Sci. 77, 593\u2013605 (2020).","journal-title":"Cell. Mol. Life Sci."},{"key":"60610_CR7","doi-asserted-by":"publisher","first-page":"17033","DOI":"10.1073\/pnas.0407902101","volume":"101","author":"O Blixt","year":"2004","unstructured":"Blixt, O. et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. USA. 101, 17033\u201317038 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60610_CR8","doi-asserted-by":"publisher","first-page":"12101","DOI":"10.1002\/0471140864.ps1210s64","volume":"64","author":"J Heimburg-Molinaro","year":"2011","unstructured":"Heimburg-Molinaro, J., Song, X., Smith, D. F. & Cummings, R. D. Preparation and analysis of glycan microarrays. Curr. Protoc. Protein Sci. 64, 12101\u2013121029 (2011).","journal-title":"Curr. Protoc. Protein Sci."},{"key":"60610_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/rheumatology\/ket342","volume":"53","author":"YS Xiong","year":"2014","unstructured":"Xiong, Y. S. et al. Increased expression of Siglec-1 on peripheral blood monocytes and its role in mononuclear cell reactivity to autoantigen in rheumatoid arthritis. Rheumatology 53, 250\u2013259 (2014).","journal-title":"Rheumatology"},{"key":"60610_CR10","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/art.22382","volume":"56","author":"MR York","year":"2007","unstructured":"York, M. R. et al. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum. 56, 1010\u20131020 (2007).","journal-title":"Arthritis Rheum."},{"key":"60610_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/08820139.2010.485625","volume":"39","author":"G Bao","year":"2010","unstructured":"Bao, G. et al. Increased Siglec-1 expression in monocytes of patients with primary biliary cirrhosis. Immunol. Investig. 39, 645\u2013660 (2010).","journal-title":"Immunol. Investig"},{"key":"60610_CR12","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1136\/annrheumdis-2016-210927","volume":"76","author":"AR Lisney","year":"2017","unstructured":"Lisney, A. R. et al. High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. Ann. Rheum. Dis. 76, 1476\u20131480 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"60610_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13075-018-1649-1","volume":"20","author":"JJ Oliveira","year":"2018","unstructured":"Oliveira, J. J. et al. The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus. Arthritis Res. Ther. 20, 152 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"60610_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12291-023-01155-y","volume":"39","author":"M Nasser","year":"2024","unstructured":"Nasser, M., Wadie, M., Farid, A. & El Amir, A. The contribution of serum sialic acid binding immunoglobulin like Lectin 1 (sSIGLEC-1) as an IFN I signature biomarker in the progression of atherosclerosis in Egyptian systemic lupus erythematosus (SLE) patients. Ind. J. Clin. Biochem. 39, 291\u2013298 (2024).","journal-title":"Ind. J. Clin. Biochem."},{"key":"60610_CR15","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer, M. et al. 2019 European league against rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 71, 1400\u20131412 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"60610_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/ard.2005.038315","volume":"65","author":"LC Lit","year":"2006","unstructured":"Lit, L. C., Wong, C. K., Tam, L. S., Li, E. K. & Lam, C. W. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 65, 209\u2013215 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"60610_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E Von Elm","year":"2007","unstructured":"Von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann. Intern. Med. 147, 573\u2013577 (2007).","journal-title":"Ann. Intern. Med."},{"key":"60610_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.rdc.2021.04.007","volume":"47","author":"T Tofighi","year":"2021","unstructured":"Tofighi, T., Morand, E. F. & Touma, Z. Systemic lupus erythematosus outcome measures for systemic lupus erythematosus clinical trials. Rheum. Dis. Clin. N Am. 47, 415\u2013426 (2021).","journal-title":"Rheum. Dis. Clin. N Am."},{"key":"60610_CR19","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/art.23456","volume":"58","author":"M Petri","year":"2008","unstructured":"Petri, M. et al. Systemic lupus international collaborating clinics renal activity\/response exercise (development of a renal activity score and renal response index). Arthritis Rheum. 58, 1784\u20131788 (2008).","journal-title":"Arthritis Rheum."},{"key":"60610_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1291\/hypres.31.1101","volume":"31","author":"E Imai","year":"2008","unstructured":"Imai, E. et al. Chronic kidney disease Japan cohort (CKD-JAC) Study: Design and methods. Hypertens. Res. 31, 1101\u20131107 (2008).","journal-title":"Hypertens. Res."},{"key":"60610_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo, S. et al. Revised equations for estimated GFR From serum creatinine in Japan. Am. J. Kidney Dis. 53, 982\u2013992 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"60610_CR22","first-page":"S1","volume":"39","author":"National Kidney Foundation","year":"2002","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39, S1\u2013S266 (2002).","journal-title":"Am. J. Kidney Dis."},{"key":"60610_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"JJ Weening","year":"2004","unstructured":"Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15, 241\u2013250 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"60610_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","volume":"143","author":"JA Hanley","year":"1982","unstructured":"Hanley, J. A. & McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29\u201336 (1982).","journal-title":"Radiology"},{"key":"60610_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32\u201335 (1950).","journal-title":"Cancer"},{"key":"60610_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1749-6632.2009.04742.x","volume":"1173","author":"F Favilli","year":"2009","unstructured":"Favilli, F. et al. IL-18 Activity in systemic lupus erythematosus. Contemporary challenges in autoimmunity. Ann. N Y Acad. Sci. 1173, 301\u2013309 (2009).","journal-title":"Ann. N Y Acad. Sci."},{"key":"60610_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/art.23186","volume":"58","author":"M Tucci","year":"2008","unstructured":"Tucci, M. et al. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: Role of interleukin-18. Arthritis Rheum. 58, 251\u2013262 (2008).","journal-title":"Arthritis Rheum."},{"key":"60610_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00109-017-1515-7","volume":"95","author":"R Strau\u00df","year":"2017","unstructured":"Strau\u00df, R. et al. Type I interferon as a biomarker in autoimmunity and viral infection: A leukocyte subset-specific analysis unveils hidden diagnostic options. J. Mol. Med. 95, 753\u2013765 (2017).","journal-title":"J. Mol. Med."},{"key":"60610_CR29","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1002\/art.30399","volume":"63","author":"A Morimoto","year":"2011","unstructured":"Morimoto, A. et al. Association of endogenous anti-interferon-\u03b1 autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 2407\u20132415 (2011).","journal-title":"Arthritis Rheum."},{"key":"60610_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/0961203306072415","volume":"15","author":"C Flower","year":"2006","unstructured":"Flower, C., Hennis, A., Hambleton, I. R. & Nicholson, G. Lupus nephritis in an Afro-Caribbean population: Renal indices and clinical outcomes. Lupus 15, 689\u2013694 (2006).","journal-title":"Lupus"},{"key":"60610_CR31","first-page":"370","volume":"11","author":"HM Al Attia","year":"2000","unstructured":"Al Attia, H. M. Lupus Nephritis among Arabs- differences with other races; emphasis on clinicopathological and serological perspectives. Saudi J. Kidney Dis. Transpl. 11, 370\u2013380 (2000).","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"60610_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejr.2012.09.005","volume":"35","author":"MA Mohsen","year":"2013","unstructured":"Mohsen, M. A., Karim, A., Abbas, S. A., Amin, M. & T. M. & Serum interleukin-18 levels in patients with systemic lupus erythematosus: Relation with disease activity and lupus nephritis. Egypt. Rheumatol. 35, 45\u201351 (2013).","journal-title":"Egypt. Rheumatol."},{"key":"60610_CR33","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.3390\/jcm13154486","volume":"13","author":"J Kosa\u0142ka-Wegiel","year":"2024","unstructured":"Kosa\u0142ka-Wegiel, J. et al. Comparison of clinical and laboratory characteristics in lupus nephritis vs. non-lupus nephritis patients\u2014a comprehensive retrospective analysis based on 921 patients. J. Clin. Med. 13, 4486 (2024).","journal-title":"J. Clin. Med."},{"key":"60610_CR34","doi-asserted-by":"publisher","first-page":"e000584","DOI":"10.1136\/lupus-2021-000584","volume":"9","author":"S McDonald","year":"2022","unstructured":"McDonald, S. et al. Predictors of treatment response in a lupus nephritis population: Lessons from the Aspreva Lupus Management Study (ALMS) trial. Lupus Sci. Med. 9, e000584 (2022).","journal-title":"Lupus Sci. Med."},{"key":"60610_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/art.23404","volume":"58","author":"R Biesen","year":"2008","unstructured":"Biesen, R. et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum. 58, 1136\u20131145 (2008).","journal-title":"Arthritis Rheum."},{"key":"60610_CR36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/annrheumdis-2024-eular.1898","volume":"83","author":"L B\u00f6ni","year":"2024","unstructured":"B\u00f6ni, L. et al. Ann. Rheum. Dis. 83, 969\u2013970 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"60610_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1182\/blood.V97.1.288","volume":"97","author":"A Hartnell","year":"2001","unstructured":"Hartnell, A. et al. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 97, 288\u2013296 (2001).","journal-title":"Blood"},{"key":"60610_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.22631\/rr.2017.69997.1017","volume":"2","author":"ST Faezi","year":"2017","unstructured":"Faezi, S. T. et al. Clinical picture of lupus nephritis in patients with systemic lupus erythematosus (SLE): Results of a large survey. Rheumatol. Res. 2, 51\u201359 (2017).","journal-title":"Rheumatol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60610-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60610-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60610-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:48:28Z","timestamp":1783342108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60610-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60610"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60610-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20784"}}